Patient of the Month for August: Guy Jones
Each member has a unique story, but all reflect the intrinsic courage of one facing the challenge of GIST. Guy Jones shares his story.
LRG Webcast: Optimizing GIST Treatment – Hebrew Subtitles
This webcast was originally recorded May 21, 2019. Follow this link for webcast with Hebrew Subtitles. Listen to the webcast - Hebrew subtitles Are you interested in optimizing your treatment? In [...]
Rozlytrek™ (entrectinib) by Approved by FDA
The FDA granted the approval of Rozlytrek™ (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC), The FDA has also granted accelerated approval to Rozlytrek for the treatment of [...]
LRG Webcast Series: When to Consider Surgery
Most GIST patients will see a surgeon at some point during their treatment. This webcast will address the issues surrounding the decision to have an operation and considers that surgical options depend on a number of factors such as tumor location, tumor size, tumor number, response to drug therapy, and risk of recurrence.
Deciphera Releases Positive Trial Results for Ripretinib
Deciphera Pharmaceuticals has released positive results from their INVICTUS Phase 3 Clinical Study of Ripretinib in patients with GIST. They have also updated results from the Phase 1 Study. Deciphera shared that "patients treated [...]
Treatment Responses in SDH-deficient GIST – LRG Science
The latest issue of LRG Science is titled, "Patient-reported Treatment Responses in Known/Likely SDH-deficient GISTS: An Analysis of The Life Raft Group Observational Registry." This study highlights the very unique research role that defines The Life Raft Group. Subscribe to LRG Science by emailing mgarland@liferaftgroup.org with the subject line SUBSCRIBE LRG SCIENCE.
LRG Releases Annual Report for 2018
In 2018, The Life Raft Group continued its dedication to patients with GIST, working diligently to enhance survival and quality of life through research, information, education, advocacy, and outreach & engagement. These efforts would [...]
Blueprint Medicines Announces Next Step for Avaprinitib
Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST Blueprint Medicines announced today that the FDA and the EMA have [...]